Group 1: General Information - The research was conducted on April 21, 2025, with the target company being Baike Biotech, which belongs to the biopharmaceutical industry [1][8] - Participating institutions include securities companies, investment companies, fund management companies, and asset management companies such as Guolian Minsheng Securities, Beijing Chengsheng, and Boyuan [2][9] Group 2: Company Performance - In 2024, the company's operating income was 1.2290841 billion yuan, a year - on - year decrease of 32.64%; net profit attributable to shareholders was 232.0938 million yuan, a decrease of 53.67%; and net profit after deducting non - recurring gains and losses was 229.8104 million yuan, a decrease of 53.42% [18] - In Q1 2025, operating income was 162.2905 million yuan, a year - on - year decrease of 39.96%; net profit attributable to shareholders was 1.0643 million yuan, a decrease of 98.24%; and net profit after deducting non - recurring gains and losses was - 3.412 million yuan, a decrease of 105.71% [18] - In 2024, varicella vaccine sales accounted for slightly over 65% of operating income with a slight increase; herpes zoster vaccine sales accounted for slightly over 20%; and nasal spray influenza vaccine had a slight year - on - year increase [19] - The company plans to distribute a cash dividend of 1.69 yuan per 10 shares (tax - included) in 2024, totaling 69.9081 million yuan (tax - included), accounting for 30.12% of the net profit attributable to shareholders [19] Group 3: Market and Strategy - The domestic herpes zoster vaccine penetration rate is still low. With the aging population, raising public awareness of the disease is crucial [19] - In 2025, the company will upgrade its marketing model, maintain its leading position in the varicella vaccine market, and expand the herpes zoster and influenza vaccine markets through various means [19][23] - The varicella vaccine is a non - immunization program vaccine. The company will continue to promote it for people over 12 years old to find new growth points [20] Group 4: International Market - The company's vaccine products are sold in countries such as India, Indonesia, Pakistan, Ghana, and Afghanistan. In 2024, varicella vaccine was exported to Afghanistan, and herpes zoster vaccine was first exported to Colombia [20] - The company is advancing the registration of varicella vaccine in Russia and expanding international sales channels through cooperation with multiple parties [20][21] Group 5: R & D Pipeline - Multiple R & D pipeline products have made key progress, including the acceptance of the listing application for liquid nasal spray influenza vaccine, and various stages of clinical trials for other products [21] - The company is also promoting R & D projects such as RSV monoclonal antibody and vaccine, and Alzheimer's disease therapeutic vaccine [21] Group 6: Marketing and Expenses - In 2024, the company established partnerships with various platforms for digital marketing of herpes zoster vaccine. As of January 1, 2025, the county - level coverage rate was about 60% [21][22] - In 2025, R & D investment is expected to increase significantly, and the sales expense ratio is expected to rise first and then fall [22]

魏来教授指出，预防工作仍是中国肝炎防控的核心与关键，"在防控策略上，我们需要整合学界、家庭 和社区力量，扎实做好分级预防与随访工作，同时借助国际专家交流契机，搭建临床与学界沟通桥梁， 积极探索切实有效的防控策略。"医疗机构是推动肝炎防治的核心力量，通过建立规范化门诊，优化诊 疗流程，提供个体化管理方案，并整合多学科资源，有助于进一步提升患者的诊疗质量和治疗成功率。 首都医科大学附属北京友谊医院、国家消化系统疾病临床医学研究中心贾继东教授介绍，近年来，各级 医疗机构依托多学科协作，优化了抗病毒治疗策略，并加强了患者随访管理，以提供更系统、更精准的 个体化治疗方案，帮助患者更好地控制病情，降低疾病进展的风险，"我们应该强化各级医院协作，发 动更多社会组织力量，全方位筑牢肝炎防治网络 。" 中国肝炎防治基金会理事长王宇指出，消除肝炎是全球共同的责任，需要政府、疾控机构、医疗机构、 医药企业、学术界及社会各方携手合作。未来，中国将继续优化防治指南，引入更多全球实践经验，探 索医防融合的新模式，确保患者能够更早发现、尽早治疗，为全球消除肝炎目标贡献力量。 新京报讯（记者张秀兰）在3月26日至30日举行的第34届亚太肝病 ...